Changes in isoform composition, structure, and functional properties of titin from mongolian gerbil (Meriones unguiculatus) cardiac muscle after space flight

I. Vikhlyantsev,A. D. Okuneva,M. D. Shpagina,Y. Shumilina,N. V. Molochkov,N. Salmov,Z. Podlubnaya

DOI: https://doi.org/10.1134/S0006297911120042

2011-12-21

Biochemistry (Moscow)

Abstract:

What problem does this paper attempt to address?

A surveillance method-oriented detection of post-operative spatial-temporal recurrence for non-small cell lung cancer.

Jun-Jie Xi,Jia-Cheng Yin,Lin Wang,Chun-Lai Lu,Qun Wang,Wei Jiang

DOI: https://doi.org/10.21037/jtd.2018.10.32

2018-01-01

Journal of Thoracic Disease

Abstract:Background: This study evaluated spatial-temporal recurrence patterns after curative resection for non-small cell lung cancer (NSCLC) to clarify and recommend appropriate post-operative surveillance. Methods: A total of 2,486 consecutive patients between January 2005 and December 2012 with NSCLC (stage I-IIIA) who underwent definitive surgical resection were retrospectively analyzed. We used a hazard rate curve to evaluate event dynamics. Disease-free survival (DFS) was evaluated by the Kaplan-Meier method. Univariate and multivariate analyses with Cox proportional hazards regression identified risk factors that predicted DFS. Results: The median follow-up was 50.1 months. Recurrences were diagnosed in 852 (34.3%) patients. Four hundred eighty-nine events first occurred in the chest, 177 in the brain, 117 in the bone, and 71 in the abdomen. Of all recurrences, 78.5% occurred in the first 3 years. Univariate and multivariate analyses identified the age at diagnosis (P<0.001), histology (P=0.023), tumor size (P<0.001), pathologic N stage (P<0.001), and grade (P=0.043) as independent risk factors for intra-thoracic recurrences. Histology (P<0.001), tumor size (P<0.001), surgical method (P=0.021), pathologic N stage (P<0.001), and grade (P=0.005) were independent to predict extra-thoracic recurrences. The hazard rate curve displayed an initial surge of time to any treatment failure during 12 months after surgery. Based on sub-group analysis, both intra- and extra-recurrences increased with stage and brain recurrences in stage IIIA occurred earlier than stage II. Hazard rate curve of brain recurrences in squamous cell carcinoma showed a moderate peak during 9-15 months. Hazard rate curves of brain and bone recurrences in adenocarcinoma displayed clear peaks at 9-27 and 15-30 months, respectively. Conclusions: Intra- and extra-thoracic recurrences correlate with different clinicopathological factors. Brain MRI and bone ECT were recommended for selected patients in particular time to early detect extrathoracic recurrences.
The Recurrence Patterns and Post-Recurrence Survivals in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma (escc) Treated with Preoperative Paclitaxel/Cisplatin-Based Chemoradiotherapy.

Hung-Yang Kuo,Jhe-Cyuan Guo,Ta-Chen Huang,Chia-Chi Lin,Min-Shu Hsieh,Jang-Ming Lee,Jason C. Cheng,Hsiu-Po Wang,Kun-Huei Yeh,Chih-Hung Hsu

DOI: https://doi.org/10.1200/jco.2016.34.4_suppl.80

IF: 45.3

2016-01-01

Journal of Clinical Oncology

Abstract:80 Background: More than half of patients (pts) with locally advanced ESCC would have disease recurrence after curative preoperative chemoradiation (CRT) followed by surgery. Whether recurrence pattern correlates with the post-recurrence survival remains uncertain. Methods: We included 131 pts with locally advanced ESCC (clinical T3N0-1M0 or T1-3N1M0 or M1a according to AJCC 6thedition) who were enrolled in 3 phase II clinical trials of preoperative CRT followed by surgery and had successfully completed CRT and surgery. These pts received preoperative twice weekly paclitaxel/cisplatin-based CRT with radiotherapy 40Gy given in 20 fractions followed by esophagectomy. When pts had first disease recurrence, we divided them into three groups according to their recurrence patterns: loco-regional recurrence (LRR), distant metastasis only (DM), and both LRR and DM (LRR+DM). Survival outcomes were compared using the Kaplan-Meier curves. Results: With a median follow-up of 34.8 months, 75 pts (57.3%) had disease recurrence (Table 1) and the median post-recurrence survival of these pts is 6.7 months (m). Among them, 24 pts (32.0%) had LRR, 19 (25.3%) pts had DM, and 32 pts (42.7%) had LRR+DM. There is no statistical difference of the post-recurrence survivals (Fig. 1) among 3 groups (5.4, 7.5, 4.9m, p = 0.43 in LRR, DM, and LRR+DM group respectively). It is noteworthy that 4 pts in the DM group with limited distant metastasis (1 had brain metastasis, 3 had lung metastasis) had long post-recurrence survival (56.2+, 51.6+, 13.8+, 13.1+m) after receiving metastasectomy with or without chemotherapy. Conclusions: The post-recurrencesurvival of locally advanced ESCC pts who received preoperative CRT followed by surgerywere similar regardless of recurrence pattern (loco-regional recurrence or both loco-regional and distant failure). However, in pts with limited metastasis, curative metastasectomy might provide the opportunity of achieving long-term survival. (The work was supported by the Grant of MOST 103-2314-B-002-092, MOST 104-2314-B-002-111- and HCH104-024)
Postoperative CT surveillance in the evaluation of local recurrence after sub-lobar resection of neoplastic lesions of the lung

Dongming Xu,Rafael E de la Hoz,Sharon Roszler Steinberger,John Doucette,Andrew Michael Pagano,Andrea Wolf,Michael Chung,Adam Jacobi

DOI: https://doi.org/10.1016/j.clinimag.2023.110030

Abstract:Objective: As indications for sub-lobar resections increase, it will become more important to identify risk factors for postsurgical recurrence. We investigated retrospectively the association between local recurrence after sub-lobar resection of neoplastic lung lesions and pre- and post-operative CT imaging and pathologic features. Materials and methods: We reviewed retrospectively neoplastic lung lesions with postoperative chest CT surveillance of sub-lobar resections in 2006-2016. We defined "suspicious" findings as nodularity ≥3 mm or soft tissue thickening ≥4 mm along the suture line and/or progression and explored their association with local recurrence. Primary lung cancer stage, tumoral invasion of lymphatics, visceral pleura or large vessels, bronchial and vascular margin distance were also assessed. Results: Our study group included 45 cases of sub-lobar resection took for either primary (n = 37) or metastatic (n = 8) lung tumors. Local recurrence was observed in 16 of those patients. New nodularity ≥3 mm or soft tissue thickening ≥4 mm along the suture line on surveillance CT was significantly associated with local recurrence (p = 0.037). Additionally, solid nodule (p = 0.005), age at surgery ≤60 years (p = 0.006), two or more sites of invasion (p < 0.0001) and poor histologic differentiation (p = 0.0001) were also significantly associated with local tumor recurrence. Of 16 patients with surveillance post-surgical PET-CT, 15 had elevated FDG uptake. Conclusion: The postoperative changes along the suture line should follow a predictable time course demonstrating a pattern of stability, thinning or resolution on CT surveillance. New or increasing postoperative nodularity ≥3 mm or soft tissue thickening ≥4 mm along the suture line requires close diagnostic work-up. Surgical pathology characteristics added prognostic value on postoperative recurrence surveillance.
Late recurrence of completely resected stage I to IIIA lung adenocarcinoma

Cameron N Fick,Elizabeth G Dunne,Nicolas Toumbacaris,Kay See Tan,Brooke Mastrogiacomo,Bernard J Park,Prasad S Adusumilli,Daniela Molena,Katherine D Gray,Smita Sihag,James Huang,Matthew J Bott,Gaetano Rocco,James M Isbell,David R Jones

DOI: https://doi.org/10.1016/j.jtcvs.2024.06.026

2024-06-29

Abstract:Objective: Research into the risk factors associated with late recurrence (>2 years after surgery) of lung adenocarcinoma is limited. We investigated the incidence of and clinicopathologic and genomic features associated with late recurrence of resected stage I-IIIA lung adenocarcinoma. Methods: We performed a retrospective analysis of patients with completely resected pathologic stage I-IIIA lung adenocarcinoma (2010-2019). Patients with a history of lung cancer, neoadjuvant therapy, or mucinous or noninvasive lung adenocarcinoma, or with follow-up of less than 2 years were excluded. Cox and logistic regression modeling were used to compare clinicopathologic variables among patients with no, early (≤2 years), and late recurrence. Comparisons of genomic mutations were corrected for multiple testing. Results: Of the 2349 patients included, 537 developed a recurrence during follow-up. Most recurrences (55% [297/537]) occurred early; 45% (240/537) occurred late. A larger proportion of late recurrences than early recurrences were locoregional (37% vs 29%; P = .047). Patients with late recurrence had more aggressive pathologic features (International Association for the Study of Lung Cancer grade 2 and 3, lymphovascular invasion, visceral pleural invasion) and higher stage than patients without recurrence. Pathologic features were similar between patients with early and late recurrence, except stage IIIA disease was more common in the early cohort. No genomic mutations were associated with late recurrence. Conclusions: Late recurrence of lung adenocarcinoma after resection is more common than previously reported. Patients without disease more than 2 years after surgery who had aggressive pathologic features at the time of resection have an elevated risk of recurrence and may benefit from more aggressive follow-up.
Computed tomography with multiplanar reformation and 3-dimensional image analysis in the preoperative evaluation of ischemic necrosis of the femoral head.

D. Sartoris,D. Resnick,D. Gershuni,Dr. Dennis K. Bielecki,M. Meyers

1986-02-01

Abstract:Computed tomography (CT) with multiplanar reformation and 3-dimensional image reconstruction were utilized preoperatively to assess the extent of infarction and collapse of the femoral head in 15 patients with ischemic necrosis. Polyethylene models of the diseased femoral heads were constructed from 3-dimensional contouring of CT data, and compared with resected specimens in patients who underwent subsequent total hip arthroplasty. Information provided by this imaging strategy was valuable in both the selection and the planning of the most appropriate surgical procedure, and models were found to represent resected head configurations with reasonable accuracy. CT combined with multiplanar reformation and 3-dimensional analysis may be the optimal preoperative means for evaluating advanced ischemic necrosis involving the femoral head.
Prediction model on disease recurrence for low risk resected stage I lung adenocarcinoma

Wang Chun Kwok,James Chung Man Ho,David Chi Leung Lam,Ko Yung Sit,Mary Sau Man Ip,Timmy Wing Kuk Au,Terence Chi Chun Tam,Ting Fung Ma

DOI: https://doi.org/10.1111/resp.14508

IF: 6.9

2023-04-29

Respirology

Abstract:We developed a post‐operative prediction model for patients with stage I adenocarcinoma based on readily available clinical information, including smoking status, disease stage and gender. The model may help personalize a follow‐up strategy and future adjuvant therapy. Background and Objective Although stage I non‐small cell lung carcinoma (NSCLC) typically carries a good prognosis following complete resection, early disease recurrence can occur. An accurate survival prediction model would help refine a follow‐up strategy and personalize future adjuvant therapy. We developed a post‐operative prediction model based on readily available clinical information for patients with stage I adenocarcinoma. Methods We retrospectively studied the disease‐free survival (DFS) of 408 patients with pathologically confirmed low‐risk stage I adenocarcinoma of lung who underwent curative resection from 2013 to 2017. A tree‐based method was employed to partition the cohort into subgroups with distinct DFS outcome and stepwise risk ratio. These covariates were included in multivariate analysis to build a scoring system to predict disease recurrence. The model was subsequently validated using a 2011–2012 cohort. Results Non‐smoker status, stage IA disease, epidermal‐growth factor receptor mutants and female gender were associated with better DFS. Multivariate analysis identified smoking status, disease stage and gender as factors necessary for the scoring system and yielded 3 distinct risk groups for DFS [99.4 (95% CI 78.3–125.3), 62.9 (95% CI 48.2–82.0), 33.7 (95% CI 24.6–46.1) months, p

respiratory system
Recurrence After Surgery for Non-small-cell Lung Cancer in the National Lung Screening Trial

Alexandra L Potter,Christina L Costantino,Raiya A Suliman,Chinmay S Haridas,Priyanka Senthil,Arvind Kumar,Nicholas R Mayne,Nikhil Panda,Linda W Martin,Chi-Fu Jeffrey Yang,Alexandra L. Potter,Christina L. Costantino,Raiya A. Suliman,Chinmay S. Haridas,Nicholas R. Mayne,Linda W. Martin

DOI: https://doi.org/10.1016/j.athoracsur.2023.06.004

IF: 5.113

2023-06-01

The Annals of Thoracic Surgery

Abstract:BACKGROUND: The objective of this study was to evaluate patterns, predictors, and long-term outcomes of recurrent disease after complete resection for early-stage non-small cell lung cancer (NSCLC) using the National Lung Screening Trial (NLST).METHODS: The frequency of recurrence in patients with pathologic stage I-II NSCLC who underwent complete resection (lobectomy or bilobectomy) in the NLST was evaluated. Predictors of increased risk of recurrence were assessed by Fine-Gray competing risks regression.RESULTS: Of the 497 patients meeting study inclusion criteria, 94 experienced a recurrence-a rate of 4.9 (95% CI, 4.0-6.0) per 100 person-years. The 5-year cumulative incidence of recurrence was 20.1% (95% CI, 16.5%-23.9%). Most patients experienced recurrences at distant sites alone (n = 47 [50.0%]) or at both locoregional and distant sites (n = 30 [31.9%]). The median time from resection to recurrence was 18.8 (10.6-30.7) months. The incidence rate of recurrence was significantly lower among patients with lung cancer detected by low-dose computed tomography screening during one of the three screening rounds of the NLST when compared with patients with lung cancer detected by chest radiography screening and patients with lung cancer not detected by any form of screening (ie, those diagnosed after a negative or missed screening exam and those diagnosed during follow-up after the three screening rounds of the NLST were completed) (P < .001). Median survival (from the date of recurrence) of patients with pathologic stage I and stage II disease who had recurrences at locoregional, distant, or both sites was 63.0, 23.1, and 9.8 months and 28.9, 8.7, and 10.2 months, respectively.CONCLUSIONS: In this analysis of NLST participants with completely resected stage I-II NSCLC, the 5-year cumulative incidence of recurrence was 20%. Nearly 82% of recurrences were at distant sites and associated with poor survival.

surgery,cardiac & cardiovascular systems,respiratory system
Genetic-pathological prediction for timing and site-specific recurrence pattern in resected lung adenocarcinoma

Chaoqiang Deng,Yang Zhang,Fangqiu Fu,Xiangyi Ma,Zhexu Wen,Zelin Ma,Shengping Wang,Yuan Li,Haiquan Chen

DOI: https://doi.org/10.1093/ejcts/ezab288

2021-06-25

Abstract:Abstract OBJECTIVES We aimed to describe accurately the timing and site-specific recurrence pattern for surgical resected lung adenocarcinoma and develop genetic-pathological risk prediction models to guide individual postoperative surveillance strategies. METHODS We retrospectively analysed radiological, pathological and sequencing data concerning 9 common oncogenic driver mutations from 1531 patients with resected lung adenocarcinoma between 2008 and 2015. The first recurrence site and time-to-recurrence were recorded. Independent risk factors were identified by multivariable regression analysis and consequently incorporated into prediction models. RESULTS With a median follow-up of 53.2 months, postoperative recurrences were noted in 483 (31.5%) patients. Bone and brain recurrence tended to occur early (median 11.7 and 17.0 months, respectively) while thorax recurrence occurred later (median 22.2 months), which was validated across different tumour stages. EGFR mutation was an independent predictor for brain and bone recurrence and KRAS mutation for early recurrence. Both internal and external validation of the nomograms for brain and bone recurrence prediction showed optimal discrimination (concordance index: internal, 0.75 and 0.81, respectively; external, 0.77 and 0.84, respectively) and calibration. Recurrence occurred relatively evenly during the follow-up period in low-risk groups but mainly occurred within 2 years in high-risk groups. CONCLUSIONS Unique biological differences exist among lung adenocarcinoma leading to distinct patterns of recurrence. These user-friendly genetic-pathological nomograms may help physicians to better stratify patients and make individual postoperative follow-up plans.

surgery,cardiac & cardiovascular systems,respiratory system
Impact of Surveillance After Lobectomy for Lung Cancer on Disease Detection and Survival

Nicholas R Mayne,Mohan K Mallipeddi,Alice J Darling,Chi-Fu Jeffrey Yang,Walid R Eltaraboulsi,Adam R Shoffner,Ibtehaj A Naqvi,Thomas A D'Amico,Mark F Berry,Nicholas R. Mayne,Mohan K. Mallipeddi,Alice J. Darling,Walid R. Eltaraboulsi,Adam R. Shoffner,Ibtehaj A. Naqvi,Thomas A. D’Amico,Mark F. Berry

DOI: https://doi.org/10.1016/j.cllc.2020.03.011

IF: 4.84

2020-09-01

Clinical Lung Cancer

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Introduction</h3><p>/Background: Existing guidelines for surveillance after non-small cell lung cancer (NSCLC) treatment are inconsistent and have relatively sparse supporting literature. This study characterizes detection rates of metachronous and recurrent disease during surveillance with computed tomography scans after definitive treatment of early stage NSCLC.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Materials and Methods</h3><p>The incidence of metachronous and recurrent disease in patients who previously underwent complete resection via lobectomy for stage IA non-small cell lung cancer at a single center from 1996 to 2010 were evaluated. A subgroup analysis was used to compare survival of patients whose initial surveillance scan was 6±3 months (early) versus 12±3 months (late) after lobectomy.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Of 294 eligible patients, 49 (17%) developed recurrent disease (14 local only, 35 distant) and 45 (15%) developed new NSCLC. Recurrent disease was found at a mean of 22±19 months and new primaries were found at a mean of 52±31 months after lobectomy (p<0.01). Five-year survival after diagnosis of recurrent disease was significantly lower than after diagnosis of second primaries (2.3% vs 57.5%, p<0.001). In the subgroup analysis of 187 patients, both disease detection on the initial scan (2% [2/94] versus 4% [4/93], p=0.44) and 5-year survival (Early 80.8% versus Late 86.7%, p=0.61) were not significantly different between the early (n=94) and the late (n=93) groups.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>Surveillance after lobectomy for stage IA NSCLC is useful for identifying both new primary as well as recurrent disease, but waiting to start surveillance until 12±3 months after surgery is unlikely to miss clinically important findings.</p>

oncology
MA01.02 Histologic Subtyping in Pathologic Stage I Lung Adenocarcinoma Provides Risk-Based Stratification for Surveillance

Y. Takahashi,T. Eguchi,K. Kameda,S. Lu,R. Vaghjiani,K. S. Tan,D. Jones,W. Travis,P. Adusumilli

DOI: https://doi.org/10.1016/j.jtho.2018.08.314

IF: 20.121

2018-01-01

Journal of Thoracic Oncology

Abstract:Current national practice guidelines (NCCN, ACCP, ESMO) recommend a uniform follow-up protocol with intensive surveillance within the first two years following lung resection for stage I NSCLC. We hypothesize that the recurrence hazard following lung resection for stage I lung adenocarcinoma (ADC) varies according to histologic subtype. A total of 1572 patients with resected pathologic stage I lung ADC were investigated. Two thoracic pathologists reviewed all tumor HandE slides (range 1-8, median 3) for histologic subtyping and percentage of each subtype. Recurrence hazard was estimated using the Kernel-Epanechnikov smoothing procedure. Association between recurrence hazard and high-grade histologic subtypes (micropapillary [MIP] and solid [SOL]) was assessed. Presence (≥5%) of these high-grade subtypes (MIP and/or SOL) was associated with significant increase of recurrence hazard compared to high-grade pattern negative (<5%) tumors (Figure): 1) patients with presence of either MIP or SOL had significant recurrence hazard peaks within two years after surgery; 2) SOL was associated with early hazard peak at the first year after surgery especially in distant recurrence hazard; 4) one-third of patients (515/1572, 33%) had no high-grade subtypes, in which the recurrence hazard was consistently very low (<2% risk each year) during the 10-year period after surgery without any hazard peak (red arrow). Our data suggest the utility of histologic subtyping for identifying patients with very low recurrence hazard, and provide foundation for establishing risk-based follow-up protocols. A potential option for low-risk patients may be omission of intensive follow-up during the first two years after surgery.
Patterns and Risks of Postoperative Recurrence in Completely Resected EGFR-mutant Non-Small Cell Lung Cancer: Prognostic Significance of Routine Immunohistochemical Markers

Jianjiao Ni,Tiantian Guo,Yuan Li,Xi Yang,Yida Li,Liqing Zou,Li Chu,Xiao Chu,Shuyan Li,Luxi Ye,Yawei Zhang,Zhengfei Zhu

DOI: https://doi.org/10.21037/tlcr.2019.12.02

2019-01-01

Translational Lung Cancer Research

Abstract:Background: Recent studies indicate that EGFR-mutant non-small cell lung cancer (NSCLC) is a heterogeneous disease with varying prognosis. In order to design an optimized surveillance strategy and identify potential candidates for adjuvant therapy, the patterns and risks of postoperative recurrence in completely resected EGFR-mutant NSCLC should be investigated, which are currently largely unknown. Methods: Consecutive patients with curatively resected EGFR-positive NSCLC receiving standard adjuvant chemotherapy without EGFR tyrosine kinase inhibitors (TKI), with or without adjuvant radiotherapy, from January 2007 to December 2017 in our cancer center, were retrospectively reviewed. Prognostic significance of ten routine immunohistochemical (IHC) markers were examined. Results: After a median follow-up of 32 (range, 5-122) months, disease recurrence occurred in 197 (37.1%) of the 531 enrolled patients. The frequencies of thoracic recurrence, brain recurrence, bone recurrence, abdominal recurrence and neck recurrence, were 69.0%, 20.8%, 20.8%, 7.1% and 6.6%, respectively. Using the Cox regression model, tumor size, Ki67, CK20, and N stage were identified as independent predictors of overall recurrence. A nomogram predicting the 1-, 2-, and 3-year cumulative rate of overall recurrence was then developed and internally validated, with a bias-corrected C-index of 0.723 (95% CI, 0.675 to 0.771) and a small extent of "over-fitting" (0.8%). Risk factors of site-specific recurrence were also discovered. Additionally, using competing risk analyses, N stage, lymphovascular invasion (LVI) and CK5/6 were found as independent predictors of loco-regional recurrence. Among patients with N2-positive disease (n=91), adjuvant radiotherapy tended to prolong disease free survival (DFS) (P=0.067), but not overall survival (OS) (P=0.271). Conclusions: This study provides the proof of concept of using routine IHC markers, along with common clinical-pathological parameters, in predicting postoperative recurrence among completely resected EGFR-mutant NSCLC. Adjuvant radiotherapy may improve DFS, but hard to prolong OS in N2-positive EGFR-mutant NSCLC without further biomarker-guided patients' selection.
[Analysis of Recurrence Patterns after Curative Resection of Stage IIIA-N2 Non-Small Cell Lung Cancer].

Jing-wei Liu,Jian Li,Gang Lin,Xue-qian Shang

DOI: https://doi.org/10.3760/cma.j.issn.0376-2491.2012.33.004

2012-01-01

Abstract:OBJECTIVE:To explore the postoperative recurrence patterns in the patients undergoing potentially curative resection of stage IIIA-N2 non-small cell lung cancer (NSCLC).METHODS:A total of 63 patients underwent curative operation from September 2004 to December 2008 at Peking University First Hospital and were pathologically diagnosed as stage IIIA-N2 NSCLC. Their clinical data were retrospectively reviewed. The follow-ups were conducted to detect the recurrent lesions. The recurrence rates at Year 2-3 were calculated by the Kaplan-Meier method while the Cox proportional hazard model was used to assess the risk factors associated with recurrence.RESULTS:The 2 and 3-year recurrence rate was 46.6% and 57.3% respectively. Only one patient experienced local failure. However, the predominant recurrence pattern was distant failure (27/28). As demonstrated by the univariate Cox regression analysis, 4 significant factors associated with recurrence and the arm of lymphatic or vascular invasion (LVI), number of positive N2 station > 1, number of positive node > 3 and involvement of subcarinal lymph nodes were found to increase the risks of failure (P < 0.05).CONCLUSION:Distant failure is the predominant pattern of postoperative recurrence in the patients of stage IIIA-N2 NSCLC. In addition to LVI, the level of positive N2 station, the number of positive N2 node and the involvement of subcarinal lymph nodes are associated with the postoperative risk of recurrence.
Gene-Expression Signature Predicts Postoperative Recurrence in Stage I Non-Small Cell Lung Cancer Patients

Yan Lu,Liang Wang,Pengyuan Liu,Ping Yang,Ming You

DOI: https://doi.org/10.1371/journal.pone.0030880

IF: 3.7

2012-01-01

PLoS ONE

Abstract:About 30% stage I non-small cell lung cancer (NSCLC) patients undergoing resection will recur. Robust prognostic markers are required to better manage therapy options. The purpose of this study is to develop and validate a novel gene-expression signature that can predict tumor recurrence of stage I NSCLC patients. Cox proportional hazards regression analysis was performed to identify recurrence-related genes and a partial Cox regression model was used to generate a gene signature of recurrence in the training dataset -142 stage I lung adenocarcinomas without adjunctive therapy from the Director's Challenge Consortium. Four independent validation datasets, including GSE5843, GSE8894, and two other datasets provided by Mayo Clinic and Washington University, were used to assess the prediction accuracy by calculating the correlation between risk score estimated from gene expression and real recurrence-free survival time and AUC of time-dependent ROC analysis. Pathway-based survival analyses were also performed. 104 probesets correlated with recurrence in the training dataset. They are enriched in cell adhesion, apoptosis and regulation of cell proliferation. A 51-gene expression signature was identified to distinguish patients likely to develop tumor recurrence (Dxy = -0.83, P<1e-16) and this signature was validated in four independent datasets with AUC >85%. Multiple pathways including leukocyte transendothelial migration and cell adhesion were highly correlated with recurrence-free survival. The gene signature is highly predictive of recurrence in stage I NSCLC patients, which has important prognostic and therapeutic implications for the future management of these patients.
The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma

Hiroaki Kanemura,Toshihide Yokoyama,Ryu Nakajima,Atsushi Nakamura,Hiroaki Kuroda,Yoshitaka Kitamura,Hiroyasu Shoda,Nobuaki Mamesaya,Yoshihiro Miyata,Tatsuro Okamoto,Kyoichi Okishio,Masahide Oki,Yuichi Sakairi,Toyofumi Fengshi Chen-Yoshikawa,Tadashi Aoki,Tatsuo Ohira,Isao Matsumoto,Kiyonobu Ueno,Takuro Miyazaki,Haruhisa Matsuguma,Hideoki Yokouchi,Tomoyuki Otani,Akihiko Ito,Kazuko Sakai,Yasutaka Chiba,Kazuto Nishio,Nobuyuki Yamamoto,Isamu Okamoto,Kazuhiko Nakagawa,Masayuki Takeda

DOI: https://doi.org/10.1016/j.jtocrr.2024.100658

2024-03-08

Abstract:Introduction: Immune checkpoint inhibitors have recently been approved for the treatment of early-stage NSCLC in the perioperative setting on the basis of phase 3 trials. However, the characteristics of such patients who are susceptible to recurrence after adjuvant chemotherapy or who are likely to benefit from postoperative immunotherapy have remained unclear. Methods: This biomarker study (WJOG12219LTR) was designed to evaluate cancer stem cell markers (CD44 and CD133), programmed death-ligand 1 (PD-L1) expression on tumor cells, CD8 expression on tumor-infiltrating lymphocytes, and tumor mutation burden in completely resected stage II to IIIA NSCLC with the use of archived DNA and tissue samples from the prospective WJOG4107 trial. Tumors were classified as inflamed or noninflamed on the basis of the PD-L1 tumor proportion score and CD8+ tumor-infiltrating lymphocyte density. The association between each potential biomarker and relapse-free survival (RFS) during adjuvant chemotherapy was assessed by Kaplan-Meier analysis. Results: A total of 117 patients were included in this study. The median RFS was not reached (95% confidence intervals [CI]: 22.4 mo-not reached; n = 39) and 23.7 months (95% CI: 14.5-43.6; n = 41) in patients with inflamed or noninflamed adenocarcinoma, respectively (log-rank p = 0.02, hazard ratio of 0.52 [95% CI: 0.29-0.93]). Analysis of the combination of tumor inflammation category and TP53 mutation status revealed that inflamed tumors without TP53 mutations were associated with the longest RFS. Conclusions: PD-L1 expression on tumor cells, CD8+ T cell infiltration, and TP53 mutation status may help identify patients with early-stage NSCLC susceptible to recurrence after adjuvant chemotherapy.
Risk of recurrence in stage I adenocarcinoma of the lung: a multi-institutional study on synergism between type of surgery and type of nodal staging

Francesco Guerrera,Filippo Lococo,Andrea Evangelista,Ottavio Rena,Luca Ampollini,Jacopo Vannucci,Luca Errico,Paolo Olivo Lausi,Luigi Ventura,Valentina Marchese,Massimiliano Paci,Pier Luigi Filosso,Alberto Oliaro,Caterina Casadio,Francesco Puma,Enrico Ruffini,Francesco Ardissone

DOI: https://doi.org/10.21037/jtd.2019.01.31

Abstract:Background: In last years, an increasing interest emerges on the role of sub-lobar resection and lobe-specific lymph nodal dissection in the treatment of early-stage lung cancer. The aim of our study was to define the impact on cumulative incidence of recurrence (CIR) of type of surgical resection and type of nodal staging in this subset of patients. Furthermore, we evaluated the possible synergism between the different kinds of procedure. Methods: An analysis of 969 consecutive stage I pulmonary adenocarcinoma patients, operated in six Thoracic Surgery Institutions between 2001 and 2013, was conducted. Type of surgical resection included lobectomy and sub-lobar resection; while pneumonectomy and bilobectomy were excluded from the analysis. Nodal staging procedures were classified in nodal sampling (NS), lobe-specific lymph node dissection (LS-ND) and systematic lymph node dissection (SND). Multivariable-adjusted comparisons for CIR was performed using Fine and Grey model, taking into account of death by any cause as competing event. In order to evaluate synergism between the different procedures, the test of interaction between type of surgical resection and type of nodal staging was carried out and results presented in a stratified way. Results: Eight-hundred forty-six (87%) patients were submitted to lobectomy, while 123 (13%) to sub-lobar resection. Four-hundred fifty-five (47%) patients received SND, 98 (10%) LS-ND and 416 (43%) NS. Two-hundred forty-seven (26%) patients developed a local/distant recurrence with a 5-year CIR of 24.2%. Multivariable-adjusted comparisons showed an independent negative effect of sub-lobar resection (HR =1.52; 95% CI: 1.07-2.17), LS-ND (HR =1.74; 95% CI: 1.16-2.6) and NS (HR =1.49; 95% CI: 1.12-1.98) on CIR. Test of interaction showed a homogeneity of results among subgroups. Conclusions: Patients affected by stage I pulmonary adenocarcinoma and submitted to lobectomy presented a significant lower recurrence rate than those submitted to sub-lobar resection. Moreover, SND presented an independent positive effect on recurrence development than other lymph node assessment strategy. Finally, lobectomy in combination with systematic lymph nodal resection showed the best results in term of CIR.
Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non–small cell lung cancers.

Xiaoru Tian,Ruotian Wang,Kun Qian,Yuanbo Li,Tengteng Wang,Lei Liu,Baodong Liu,Lei Su,Peilong Zhang,Xin Zhao,Kai Wang,Yuanyuan Xiong,Yi Zhang

DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.8533

IF: 45.3

2022-06-01

Journal of Clinical Oncology

Abstract:8533 Background: Circulating tumor DNA (ctDNA) has emerged as a potential novel biomarker to predict molecular residue disease in lung cancer after definitive treatment. Herein, we investigated the value of ctDNA in prognosing risk of relapse and monitoring the effect of adjuvant therapy in surgical non-small cell lung cancer (NSCLC) patients. Methods: Forty-one surgical NSCLC patients were enrolled. Tumor tissues were collected at surgery and subjected to targeted NGS of 1021 cancer-related genes. The serial peripheral blood samples were collected at postoperative one month and then at every third or sixth month and subjected to ultra-deep targeted NGS covering 338 genes. Results: From 41 eligible patients including 18 patients with stage I disease, 2 with stage II and 21 with stage III, 41 tumor tissues and 137 plasma samples were enrolled and successfully tested. In tissue samples, 323 somatic variations were identified, with a median of 8 (range, 1-21) gene variations detected in each patient. TP53 was the most common mutation (63.41%), followed by EGFR (58.53%), LRP1B (17.07%) and KRAS (14.63%). The first-postoperative ctDNA positive was found in 13 of 41 patients (31.71%), 9 stage III, 2 stage II and 2 stage I. During a median 9.47 months follow-up, 38.46% (5/13) patients with detectable ctDNA in the first postoperative blood sample experienced recurrence, while 3.57% (1/28) patients with undetectable ctDNA ultimately recurred. The DFS can be stratified by the first-postoperative ctDNA status, with ctDNA-positive groups having significantly reduced DFS (p < 0.05). We detected ctDNA in at least one time point after surgery in 17 patients (41.46%), 5 of them (29.41%) experienced recurrence. Twenty-four patients without ctDNA detection during postoperative surveillance, one (4.17%) of them ultimately recurred. Serial ctDNA detection revealed disease recurrence ahead of radiologic imaging by a median of 5.25 months (range, 0.98-14.19). Among the 41 patients, 6 patients had surgery alone, 35 patients received adjuvant therapy. For these 35 patients, ctDNA analysis can stratify patients before and after adjuvant therapy. Recurrence ratio was 33.33% (4/12) in patients with detectable and 4.34% (1/23) in patients with undetectable ctDNA before adjuvant therapy. For ctDNA analysis after adjuvant therapy, no patients (11/11) with negative ctDNA had disease-recurrence while 33.33% (1/3) patients with positive ctDNA experienced recurrence. All four patients with clearance ctDNA by adjuvant therapy remained disease free. Conclusions: For NSCLC patients, postoperative ctDNA is a prognostic marker, which reveals disease recurrence ahead of radiographic examination. Importantly, ctDNA-detecting may facilitate personalized adjuvant therapy, and applying adjuvant therapy to the patients with detectable ctDNA could bring clinical benefits for them.

oncology
Prognostic Factors in Curatively Resected Pathological Stage I Lung Adenocarcinoma

Yikun Yang,Yousheng Mao,Lin Yang,Jie He,Shugeng Gao,Juwei Mu,Qi Xue,Dali Wang,Jun Zhao,Yushun Gao,Zhirong Zhang,Ningning Ding,Ding Yang

DOI: https://doi.org/10.21037/jtd.2017.11.65

2017-01-01

Journal of Thoracic Disease

Abstract:Background: Patients with pathological stage I (p I) lung adenocarcinoma show variabilities in prognosis even after complete resection. The factors resulting in heterogeneities of prognosis remain controversy. The aim of this study was to identify the risk factors affecting recurrence/metastasis and survival in patients with curatively resected p I lung adenocarcinoma. Methods: A total of 252 patients with p I lung adenocarcinoma underwent curative resection between January 1st, 2009 to September 30th, 2011 were retrospectively reviewed to analyze the associations of recurrence and survival with the following clinicopathological variables: gender, age, cigarette smoking, family cancer history, tumor size, TNM stage, tumor differentiation, visceral pleural invasion, bronchial involvement, lymphovascular invasion, postoperative adjuvant treatment, pathological subtypes and micropapillary pattern. Results: Among those 252 patients, 48 had local recurrence or distant metastasis, the rest 204 patients had no relapse until the last follow-up. Cox univariate survival analysis revealed that tumor size (P<0.001), TNM stage [disease-free survival (DFS), P<0.001; overall survival (OS), P=0.004], tumor differentiation (P<0.001), bronchial involvement (P<0.001), lymphovascular invasion (DFS, P=0.021; OS, P=0.001) and micropapillary pattern (DFS, P<0.001; OS, P=0.003) were significantly associated with DFS and OS, while cigarette smoking (P=0.029) and pathological subtypes (P=0.041) were found to be risk factors for DFS either. In multivariate analysis, tumor differentiation (P<0.001) was an independent risk factor for both DFS and OS, TNM stage (P=0.007), bronchial involvement (P=0.004) and micropapillary pattern (P=0.001) only for DFS, while tumor size (P=0.009) and lymphovascular invasion (P=0.010) were found to be independent risk factors only for OS. Conclusions: Tumor size, TNM stage, tumor differentiation, bronchial involvement, lymphovascular invasion and micropapillary pattern could be considered as risk factors for predicting local recurrence or distant metastasis and survival in curatively resected p I lung adenocarcinoma patients.
Risk Factors of Postoperative Recurrence and Potential Candidate of Adjuvant Radiotherapy in Lung Adenosquamous Carcinoma

Jianjiao Ni,Zhiqin Zheng,Juan Li,Yuan Li,Min Fan,Liang Liu

DOI: https://doi.org/10.21037/jtd-20-1979

2020-01-01

Journal of Thoracic Disease

Abstract:Background: Adenosquamous carcinoma (ASC) is a rare and aggressive histologic subtype of non-small cell lung cancer (NSCLC). Little is known about the prognostic significance of routine immunohistochemical (IHC) markers and clinical value of adjuvant radiotherapy in completely resected lung ASC. Methods: Consecutive patients with pathologically confirmed lung ASC receiving curative resection from January 2007 to December 2017 at our center were retrospectively reviewed. The prognostic significance of 14 routine IHC markers and potential candidate of adjuvant radiotherapy were investigated. Results: With a median follow up of 35 (range, 3.0-138) months, 95 out of the 176 enrolled patients had disease recurrence. The 1-, 3- and 5-year cumulative rate of recurrence was 25.8%, 55.8% and 63.1%, respectively. Using the Cox proportional hazard regression model, T stage, N stage, lymphovascular invasion (LVI), expression of CEA, expression of p53, but not EGFR mutations or expression of the other 12 IHC markers (CK20, CK5/6, PE10, ERCC1, Napsin A, RRM1, Ki67, CK7, P63, EGFR, HER2, TTF1), were significantly associated with postoperative recurrence. N stage, expression of CEA and LVI were identified as independent prognosticators of overall recurrence. Using competing risk methodology and distant recurrence chosen as a competing risk, T stage and N stage were identified as significant risk factors of loco-regional recurrence. Moreover, adjuvant radiotherapy significantly improved disease-free survival (DFS) (P=0.002) and was associated with non-significant longer overall survival (OS) (P=0.078) among 95 patients with either pathological T3-4 or N+ disease (collectively defined as pT(3-4)/N+ disease). Conclusions: This study provides the proof of concept for using routine IHC markers, along with common clinic-pathological parameters, in predicting postoperative recurrence and identifying potential candidate for adjuvant radiotherapy in completely resected lung ASC.
Preoperative predictors for recurrence sites associated with poor post-recurrence survival after surgery of non-small cell lung cancer: a multicenter study

Tetsuya Isaka,Hiroyuki Adachi,Kotaro Murakami,Jun Miura,Noritake Kikunishi,Naoko Shigeta,Yujin Kudo,Yoshihiro Miyata,Morihito Okada,Norihiko Ikeda,Hiroyuki Ito

DOI: https://doi.org/10.1186/s12885-023-11582-y

IF: 4.638

2023-11-06

BMC Cancer

Abstract:Background: The recurrence site that influences post-recurrence survival (PRS) in patients with non-small cell lung cancer (NSCLC) undergoing surgery and the preoperative predictors of recurrence remain unclear. Methods: Cohorts 1 and 2 had 4520 (who underwent complete resection for p-stage 0-IIIA NSCLC) and 727 (who experienced recurrence after surgery) patients, respectively. The initial sites of recurrence were the lungs (309 cases), thoracic lymph nodes (225 cases), pleura (112 cases), bone (110 cases), central nervous system (86 cases), adrenal gland (25 cases), abdomen (60 cases), cervical and axillary lymph nodes (38 cases), chest wall (13 cases), skin (5 cases), and eye and tongue (3 cases). For cohort 2 analysis, the initial recurrence site that resulted in poor PRS was analyzed by multivariable analysis using a Cox proportional hazard model. For cohort 1 analysis, the preoperative predictors of recurrence patterns with poor PRS were analyzed by multivariable analysis using a logistic regression model. Results: In cohort 2 analysis, recurrence in the central nervous system (hazard ratio [HR], 1.70; p < 0.001), bone (HR, 1.75; p < 0.001), abdomen (HR, 2.39; p < 0.001), and pleura (HR, 1.69; p < 0.001) were independent poor prognostic recurrent sites for PRS and they were high-risk sites (HRS). Intrathoracic lymph nodes, cervical and axillary lymph nodes, lungs, chest wall, adrenal gland, eye and tongue, and skin were low-risk sites (LRS) that did not affect PRS. Patients with multiple LRS without HRS recurrence had a worse prognosis than those with a single LRS without HRS recurrence (5-year PRS 20.2% vs. 37.7%, p < 0.001) and were comparable to those with HRS recurrence (p = 1.000). In cohort 1 analysis, preoperative predictors for HRS and multiple LRS recurrences were positron emission tomography (PET) maximum standardized uptake value (maxSUV) ≥ 3.2 (HR, 5.09; p < 0.001), clinical nodal metastasis (HR, 2.00; p < 0.001), tumor size ≥ 2.4 cm (HR, 1.96; p < 0.001) and carcinoembryonic antigen (CEA) ≥ 5 ng/ml (HR, 1.41; p = 0.004). The cumulative incidence rates of HRS and multiple LRS recurrences within 5 years were 55.9%, 40.9%, 26.3%, 11.1%, and 3.5% (p < 0.001) in patients with 4, 3, 2, 1 and 0 of the above risks, respectively. Conclusions: HRS and multiple LRS were vital recurrences associated with poor PRS. Preoperative PET maxSUV, clinical nodal metastasis, tumor size, and CEA level predicted the incidence of vital recurrence.
Risk Factors for Recurrence after Complete Resection of Pathological Stage N2 Non-Small Cell Lung Cancer

Guangliang Qiang,Chaoyang Liang,Qiduo Yu,Fei Xiao,Zhiyi Song,Yanchu Tian,Bin Shi,Deruo Liu,Yongqing Guo

DOI: https://doi.org/10.1111/1759-7714.12159

IF: 3.223

2014-01-01

Thoracic Cancer

Abstract:BACKGROUND:Tumor recurrence is the most common cause of treatment failure, especially after complete resection of pathological stage N2 non-small cell lung cancer (NSCLC). In this study, we investigated the clinicopathological characteristics in order to identify independent risk factors for postoperative recurrence.METHODS:Between January 2001 and December 2013, 96 patients who underwent surgical resection for pathological N2 NSCLC were retrospectively reviewed. Recurrence-free survival (RFS) was calculated by the Kaplan-Meier method to explore risk factors, while the Cox proportional hazard model was used to assess independent predictors.RESULTS:The median and five-year RFS rates were 15 months and 27.4%, respectively. Univariate analysis showed a significantly poorer prognosis for non-regional N2 metastasis, more than three metastatic N2 lymph nodes, multiple N2 station, and multiple N2 zone involvement. Multivariate analysis demonstrated that non-regional N2 metastasis (hazard ratio [HR] 1.857, 95% confidence interval [CI] 1.061-3.249, P = 0.030) and more than three metastatic N2 lymph nodes (HR 2.555, 95% CI 1.164-5.606, P = 0.019) were independent risk factors for RFS. Additionally, the incidence of non-regional N2 metastasis was higher in patients with a primary tumor in the left lower (57.1%) or right lower lobe (48.1%), followed by left upper (31.8%), right middle (14.3%) and right upper lobe (7.7%).CONCLUSION:The combination of the distribution and number of metastatic N2 lymph nodes provides a more accurate prediction for N2 NSCLC regarding recurrence. Non-regional N2 metastasis could occur with a primary tumor in any lobe, but occurs more frequently in the lower lobe.

Changes in isoform composition, structure, and functional properties of titin from mongolian gerbil (Meriones unguiculatus) cardiac muscle after space flight

A surveillance method-oriented detection of post-operative spatial-temporal recurrence for non-small cell lung cancer.

The Recurrence Patterns and Post-Recurrence Survivals in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma (escc) Treated with Preoperative Paclitaxel/Cisplatin-Based Chemoradiotherapy.

Postoperative CT surveillance in the evaluation of local recurrence after sub-lobar resection of neoplastic lesions of the lung

Late recurrence of completely resected stage I to IIIA lung adenocarcinoma

Computed tomography with multiplanar reformation and 3-dimensional image analysis in the preoperative evaluation of ischemic necrosis of the femoral head.

Prediction model on disease recurrence for low risk resected stage I lung adenocarcinoma

Recurrence After Surgery for Non-small-cell Lung Cancer in the National Lung Screening Trial

Genetic-pathological prediction for timing and site-specific recurrence pattern in resected lung adenocarcinoma

Impact of Surveillance After Lobectomy for Lung Cancer on Disease Detection and Survival

MA01.02 Histologic Subtyping in Pathologic Stage I Lung Adenocarcinoma Provides Risk-Based Stratification for Surveillance

Patterns and Risks of Postoperative Recurrence in Completely Resected EGFR-mutant Non-Small Cell Lung Cancer: Prognostic Significance of Routine Immunohistochemical Markers

[Analysis of Recurrence Patterns after Curative Resection of Stage IIIA-N2 Non-Small Cell Lung Cancer].

Gene-Expression Signature Predicts Postoperative Recurrence in Stage I Non-Small Cell Lung Cancer Patients

The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma

Risk of recurrence in stage I adenocarcinoma of the lung: a multi-institutional study on synergism between type of surgery and type of nodal staging

Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non–small cell lung cancers.

Prognostic Factors in Curatively Resected Pathological Stage I Lung Adenocarcinoma

Risk Factors of Postoperative Recurrence and Potential Candidate of Adjuvant Radiotherapy in Lung Adenosquamous Carcinoma

Preoperative predictors for recurrence sites associated with poor post-recurrence survival after surgery of non-small cell lung cancer: a multicenter study

Risk Factors for Recurrence after Complete Resection of Pathological Stage N2 Non-Small Cell Lung Cancer